Abundant glutamic acid decarboxylase (GAD)‐reactive B cells in gad‐antibody–associated neurological disorders

High levels of antibodies against glutamic acid decarboxylase (GAD) are observed in patients with different neurological disorders, but cells producing these autoantibodies are largely unexplored. We detect circulating GAD‐reactive B cells in peripheral blood that readily differentiate into antibody...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology 2019-03, Vol.85 (3), p.448-454
Hauptverfasser: Thaler, Franziska S., Thaller, Anna L., Biljecki, Michelle, Schuh, Elisabeth, Winklmeier, Stephan, Mahler, Christoph F., Gerhards, Ramona, Völk, Stefanie, Schnorfeil, Frauke, Subklewe, Marion, Hohlfeld, Reinhard, Kümpfel, Tania, Meinl, Edgar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:High levels of antibodies against glutamic acid decarboxylase (GAD) are observed in patients with different neurological disorders, but cells producing these autoantibodies are largely unexplored. We detect circulating GAD‐reactive B cells in peripheral blood that readily differentiate into antibody‐producing cells. These cells are highly elevated in most patients with GAD‐antibody–associated disorders (n = 15) compared to controls (n = 19). They mainly produce GAD65 antibodies of the IgG1 and IgG4 subclasses and are as abundant as B cells reactive for common recall antigens. Bone marrow cells represent an additional source of GAD antibodies. The identification of GAD‐antibody–producing cells has implications for the selection of cell‐specific biologics. ANN NEUROL 2019;85:448–454.
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.25414